OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Hematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome	54
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon	54
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management	47
Do we need more guidance on thrombophilia testing? Challenges and special considerations	37
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly	36
Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic	27
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia	27
What is the future of digital tools to help manage pain in sickle cell disease patients?	24
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	24
Treatment patterns and blood count control in 10,112 patients with polycythemia vera	23
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP	22
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease	22
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis	21
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis	21
Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management	20
Correlation between hematocrit and the risk of common human cancers: results of a 1999–2020 observational survey and Mendelian randomization analysis	19
Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management	18
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective	16
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations	15
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia	15
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B	15
Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors	15
The future of siRNA-mediated approaches to treat von Willebrand disease	14
Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients	14
Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women	13

Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review	12
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera	12
Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia	12
Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A	12
Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter!	12
Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future	12
Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review	11
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations	11
Voxelotor for the treatment of sickle cell disease in pediatric patients	11
Patient-centered care in von Willebrand disease: are we there yet?	11
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients	10
Development and internal validation of a prediction model for patients with hematologic diseases of fall risk: a cohort study	10
Thrombotic events in children and adolescent patients with SARS-CoV-2 infection: a systematic review with meta-analysis on incidence and management	10
Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?	10
New directions to develop therapies for people with hemophilia	10
Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19	10
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes	10
Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies	9
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours	9
Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in the United States	9
Is the occurrence of deep vein thrombosis related to the fracture site? A two-sample Mendelian randomization study	9
Optimizing long-term joint health in the treatment of hemophilia	9
The National Hemophilia Foundation’s State of the Science Research Summit: the foundation of a national research blueprint for inherited bleeding disorders	9
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors	9
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia	9
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding	9
Rivaroxaban plus aspirin after lower–extremity revascularization	9
What is the importance of monitoring iron levels in different organs over time with magnetic resonance imaging in transfusion-dependent thalassemia patients?	9
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria	8
Long-term follow-up of patients with hairy cell leukemia in the south of Iran	8
Bad players in AL amyloidosis in the current era of treatment	8
Hematology in the post-COVID era: spotlight on vaccine-induced immune thrombotic thrombocytopenia and a conceptual framework (the 4P’s) for anti-PF4 diseases	8
Role of volumetric analyses on [¹⁸F]FDG PET/CT in pediatric Hodgkin lymphoma	8
Lived experience experts: a name created by us for us	8
The association between hemoglobin level, anemia, and hypertension among adolescents in Sudan: a multicenter cross-sectional study	8
Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients	8
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS	8
Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia	7
The impact of oral health promotion on the quality of life of children with bleeding disorders: fighting misconceptions	7
Advances in our understanding of genetic markers and targeted therapies for pediatric LCH	7
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions	7
Indicators of an increased risk of therapy-related myeloid neoplasms in lymphoma patients: how can we best evaluate severe impairment of bone marrow function?	7
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis	7
Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura	7
Monoclonal antibodies used for the management of hemataological disorders	7
Trends of chronic lymphocytic leukemia incidence and mortality in the United States: a population-based study over the last four decades	7
Problems faced by people with hemophilia aged 18–35 years in social life: a qualitative study	7
Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?	7
An update on novel therapies for treating patients with arterial thrombosis	7
Sickle cell disease in gulf cooperation council countries: a systematic review	7

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders	7
Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials	7
Hematological disorders in children with Down syndrome	7
Genetic variant of endothelial protein C receptor genes and its serum level in B thalassemic children	7
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency	6
Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review	6
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia	6
A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma	6
Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma	6
Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies	6
Circ_0035381 contributes to the progression of acute myeloid leukemia via regulating miR-186-5p/CDCA3 pathway	6
An observational study of disease management in adult patients with polycythemia vera: results from a large U.S. claims database	6
NSAIDS/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy	6
Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia	6
Targeting von Willebrand disease: the current status and future directions of management therapies	6
Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them	6
Identifying prognostic gene panels in acute myeloid leukemia	6
Exploring health disparities in diagnosing multiple myeloma	6
Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia	6
Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors	6
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes	6
Challenges in the diagnosis of thrombotic thrombocytopenic purpura	6
Exploring the genetic relationship between deep vein thrombosis and plasma protein: a new research idea	6
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia	6
Curative effect of motherwort combined with ethinylestradiol-cyproterone acetate on dysfunctional uterine bleeding	6
Kompetitive allele specific PCR (KASP) based genotyping of sickle gene in the selected sub-ethnic tribal population of Gujarat and Madhya Pradesh	6
Effectiveness of myofascial therapy (MFT) along with traditional physiotherapy and intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy: a randomized control tr	5
CircPTK2 promotes cell viability, cell cycle process, and glycolysis and inhibits cell apoptosis in acute myeloid leukemia by regulating miR-582-3p/ALG3 axis	5
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin	5
Modifiable lifestyle risk factors and survival after diagnosis with multiple myeloma	5
HIV-1 infection in sickle cell disease and sickle cell trait: role of iron and innate response	5
The role of staging in multiple myeloma	5
Procalcitonin as a diagnostic marker for infection in sickle cell disease	5
Five decades of successive establishment of hemophilia care in Thailand	5
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia	5
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review	5
Vasculopathy among children and adolescents with sickle cell disease: the crosstalk with annexin A1, vitamin D, and myocardial iron overload	5
Proactive measures to reduce maternal mortality and post-partum hemorrhage in sub-Saharan Africa: the hematology perspective	5
A new decade awaits sticky platelet syndrome: where are we now, how do we manage and what are the complications?	5
Revolutionizing hypertension treatment: aprocitentan’s dual action against resistant hypertension	5
How clinicians and persons with hemophilia may approach shared decision-making	5
Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?	5